Program
Nivolumab
Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.
Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,031 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 12410 open or running | phase 4since Nov 2, 2015 | Feb 27, 2007 | Feb 5, 2027phase 2 · NCT06946797 |
| Ono Pharmaceuticalits history only | 144 open or running | phase 3since Oct 9, 2014 | Jan 26, 2009 | Dec 31, 2027phase 2 · NCT04566380 |
| Pfizerits history only | 20 open or running | phase 2since Oct 7, 2015 | Oct 7, 2015 | none ahead |
| ella-therapeutics-ltdits history only | 10 open or running | phase 2since Aug 13, 2020 | Aug 13, 2020 | none ahead |
| excellabio-llcits history only | 10 open or running | phase 2since Oct 20, 2017 | Oct 20, 2017 | none ahead |
| nilogen-oncosystemsits history only | 10 open or running | early phase 1since Dec 3, 2017 | Dec 3, 2017 | none ahead |
| rampart-health-l-l-cits history only | 10 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| USWM CTits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 47 studies since Mar 28, 2017.
- Oct 6, 2021Phase 3 study in Stomach NeoplasmsOno Pharmaceutical · NCT05144854 · 626 enrolled · Japan, South Korea, Taiwan
- Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
- Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinBristol-Myers Squibb · NCT05255601 · 5 enrolled · United States, Australia, France and more
- Aug 9, 2022Phase 2 study in MelanomaBristol-Myers Squibb · NCT05496192 · Germany, Spain
- Aug 10, 2022Phase 1 study in Advanced Solid TumorsBristol-Myers Squibb · NCT05498480 · 6 enrolled · China
- Oct 26, 2022USWM CT’s first study: phase 2 study in Ovarian NeoplasmsNew to USWM CTUSWM CT · NCT05601752 · 21 enrolled · United States, Canada, France and more
- Nov 15, 2022Phase 3 study in MelanomaBristol-Myers Squibb · NCT05625399 · 579 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 2 study in MelanomaBristol-Myers Squibb · NCT06101134 · 100 enrolled · United States, Chile, Greece and more
- Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06561386 · 1,000 planned · United States, Argentina, Australia and more
- Sep 30, 2024Phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941 · 23 planned · Japan
- Apr 13, 2025Phase 2 study in Richter's TransformationOno Pharmaceutical · NCT06936943 · 14 planned · Japan
- Apr 25, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797 · 76 enrolled · United States, Brazil, Chile and more
- Mar 5, 2026Phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543 · 40 planned · India
- Oct 14, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT04566380
Ahead
- Feb 5, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT06946797
- Dec 31, 2027Primary completion: phase 2 study in Pan-tumorOno Pharmaceutical · NCT04566380
- Jan 31, 2029Primary completion: phase 2 study in Rhabdoid TumorOno Pharmaceutical · NCT06622941
- May 26, 2029Primary completion: phase 4 study in MelanomaBristol-Myers Squibb · NCT07459543
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 145 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07459543Melanoma · India | 4 | Not yet recruiting | Bristol-Myers Squibb | May 26, 2029 | 40 |
| NCT06946797Carcinoma, Non-Small-Cell Lung · United States, Brazil, Chile and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Feb 5, 2027 | 76 |
| NCT06936943Richter's Transformation · Japan | 2 | Recruiting | Ono Pharmaceutical | Jul 31, 2029 | 14 |
| NCT06622941Rhabdoid Tumor · Japan | 2 | Recruiting | Ono Pharmaceutical | Jan 31, 2029 | 23 |
| NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Jul 30, 2030 | 1,000 |
| NCT06101134Melanoma · United States, Chile, Greece and more | 2 | Active, not recruiting | Bristol-Myers Squibb | Apr 10, 2025 | 100 |
| NCT05625399Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Aug 4, 2025 | 579 |
| NCT05601752Ovarian Neoplasms · United States, Canada, France and more | 2 | Terminated | USWM CT | Sep 30, 2025 | 21 |
| NCT05498480Advanced Solid Tumors · China | 1 | Completed | Bristol-Myers Squibb | Jan 18, 2024 | 6 |
| NCT05496192Melanoma · Germany, Spain | 2 | Withdrawn | Bristol-Myers Squibb | Jun 24, 2024 | 0 |
| NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more | 2 | Terminated | Bristol-Myers Squibb | Dec 3, 2025 | 5 |
| NCT05136677Mesothelioma, Malignant · China | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2025 | 102 |
| NCT05144854Stomach Neoplasms · Japan, South Korea, Taiwan | 3 | Active, not recruiting | Ono Pharmaceutical | Oct 20, 2025 | 626 |
| NCT04567615Carcinoma, Hepatocellular · Argentina, Brazil, Chile and more | 2 | Completed | Bristol-Myers Squibb | Aug 31, 2023 | 266 |
| NCT04566380Pan-tumor · Japan, South Korea, Taiwan | 2 | Recruiting | Ono Pharmaceutical | Dec 31, 2027 | 70 |
| NCT04521075Melanoma · Israel | 2 | UNKNOWN | ella-therapeutics-ltd | Jul 1, 2022 | 42 |
| NCT04513522Kidney Neoplasms · India | 4 | Completed | Bristol-Myers Squibb | Jan 4, 2024 | 101 |
| NCT04495010Melanoma · United States, Australia, Austria and more | 2 | Withdrawn | Bristol-Myers Squibb | Feb 28, 2024 | 0 |
| NCT04340193Liver Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Dec 12, 2023 | 26 |
| NCT04311710Neoplasms · United States, Italy, New Zealand | 1 | Terminated | Bristol-Myers Squibb | Jan 14, 2021 | 21 |
| NCT04209114Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jun 7, 2023 | 114 |
| NCT04151563Carcinoma · United States, Argentina, Belgium and more | 2 | Withdrawn | Bristol-Myers Squibb | Dec 17, 2023 | 0 |
| NCT04149574Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Bristol-Myers Squibb | Oct 31, 2023 | 13 |
| NCT04109066Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 16, 2023 | 521 |
| NCT04100018Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 1,030 |
| NCT04099251Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jun 28, 2022 | 790 |
| NCT04088500Carcinoma, Renal Cell · United States, Canada | 2 | Terminated | Bristol-Myers Squibb | Nov 15, 2021 | 5 |
| NCT04075604Breast Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Jul 27, 2021 | 23 |
| NCT04090775Metastatic Prostatic Adenocarcinoma · United States | 2 | Completed | rampart-health-l-l-c | Jul 30, 2020 | 12 |
| NCT04039607Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jul 9, 2026 | 732 |
| NCT04026412Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 22, 2024 | 925 |
| NCT04025879Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Jul 26, 2023 | 461 |
| NCT04008030Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | Aug 28, 2024 | 839 |
| NCT03980314Melanoma · United States, Argentina, Australia and more | 1 | Completed | Bristol-Myers Squibb | Mar 4, 2021 | 261 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Aug 25, 2029 | 1,500 |
| NCT03770299Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Bristol-Myers Squibb | Mar 14, 2023 | 0 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Bristol-Myers Squibb | Feb 27, 2022 | 0 |
| NCT03668119Pan Tumor · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | May 3, 2022 | 212 |
| NCT03661320Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 16, 2026 | 855 |
| NCT03656718Neoplasms by Site · United States, Argentina, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Sep 7, 2022 | 139 |
| NCT03646123Hodgkin Disease · United States, Australia, Czechia and more | 2 | Terminated | Pfizer | Nov 7, 2022 | 255 |
| NCT03519256Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Terminated | Bristol-Myers Squibb | Aug 22, 2022 | 142 |
| NCT03444766Carcinoma, Non-Small-Cell Lung · India | 4 | Completed | Bristol-Myers Squibb | Jul 17, 2019 | 100 |
| NCT03414983Colorectal Neoplasms · United States, Canada, Japan and more | 3 | Completed | Bristol-Myers Squibb | Feb 1, 2021 | 196 |
| NCT03383458Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bristol-Myers Squibb | May 27, 2026 | 545 |
| NCT03377361Colorectal Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Nov 4, 2024 | 325 |
| NCT03371992Carcinoma, Non-Small-Cell Lung · United States | Early 1 | UNKNOWN | nilogen-oncosystems | Dec 2020 | 25 |
| NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more | 3 | Completed | Bristol-Myers Squibb | Oct 14, 2019 | 74 |
| NCT03338790Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Jan 13, 2021 | 292 |
| NCT03342417Ovarian Neoplasms · United States | 2 | Terminated | excellabio-llc | May 29, 2019 | 5 |
| NCT03215706Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Aug 16, 2019 | 719 |
| NCT03195491Lung Neoplasms · China, Thailand | 3 | Completed | Bristol-Myers Squibb | Jun 8, 2021 | 400 |
| NCT03195478Solid Tumor · China | 2 | Completed | Bristol-Myers Squibb | Jan 5, 2024 | 37 |
| NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Jan 18, 2021 | 970 |
| NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 12, 2020 | 701 |
| NCT03138512Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Sep 28, 2023 | 1,641 |
| NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico | 3 | Terminated | Bristol-Myers Squibb | Feb 22, 2021 | 23 |
| NCT03117049Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Taiwan | 3 | Completed | Ono Pharmaceutical | Feb 10, 2020 | 550 |
| NCT03130959Various Advanced Cancer · United States, Australia, Brazil and more | 2 | Completed | Bristol-Myers Squibb | Mar 10, 2020 | 166 |
| NCT03098550Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Bristol-Myers Squibb | Jul 6, 2020 | 105 |
How it is read
Names in the registry
- “Nivolumab”, 115 entries
- “nivolumab”, 18 entries
- “ONO-4538”, 13 entries
- “BMS-936558 (MDX-1106)”, 5 entries
- “Nivolumab + Relatlimab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 36 studies
- Melanoma, 21 studies
- Carcinoma, Renal Cell, 11 studies
- Carcinoma, Hepatocellular, 6 studies
- Colorectal Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.